Showing posts with label Vaccine Adjuvants Market trends. Show all posts
Showing posts with label Vaccine Adjuvants Market trends. Show all posts

Tuesday, 14 September 2021

Vaccine Adjuvants Market Size, Recent Advancement & Scope Top Trends

 The Global Platelet Aggregation Devices Market Size Is Expected To Reach USD 1,556.8 Million by 2027 according to a new study by Polaris Market Research. Platelet aggregation is the biological process where the platelet cells are employed in a process to prevent bleeding through vaso-constriction for rapid clot formation. The whole process is mediated via platelet aggregating factor (PAF). The quantitative and qualitative defects of platelets lead to increased bleeding. The high reactivity of platelets in the patients having anti-platelet therapy results in thromboembolic complications.

 

Platelet function related disorders can be either inherited or acquired. The inherited platelet function disorders include Von Willebrand disease, Glanzmann’s thrombasthenia, Bernard-Soulier syndrome, Storage pool disease. The acquired platelet dysfunction may be caused by chronic conditions such as kidney failure (uremia), Myelodysplastic syndrome (MDS), Leukemias (chronic myeloid leukemia or CML; acute myeloid leukemia or AML).

 

Request A Sample Report at :  https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-sample

 

Some acquired platelet disorders are temporary because of the decreased function of platelets due to anti-platelet medications, non-steroidal anti-inflammatory drugs (NSAIDs), tricyclic antidepressants, antihistamines and some antibiotics. The platelet function testing is transitioned from diagnostics for heritable diseases to a functional one for platelet functional therapies. The rapid usage of anti-platelet therapy, mainly dual anti-platelet therapy has changed the focus of platelet function testing from diagnostics to therapeutics.

The market is driven by few notable factors such as the recent surge in infectious diseases (COVID-19) requiring rapid serological tests, innovations in platelet aggregation mechanisms, systems and consumables, and worldwide rise in chronic ailments. Specialized tests based on platelet aggregation include light transmission platelet aggregometry on platelet-rich plasma (LTA), impedance whole blood aggregometry (WBA), Lumi-aggregometry and flow cytometry.

 

Automated haematology analyzers can be used to obtain platelet counts over a wide range of values using optical counting methods like light scatter or fluorescence. Screening tests such as prothrombin time (PT) or activated partial thromboplastin time (aPTT) are more standardized and fully automated.

 

Request for Discount Pricing with Your Specific Research Needs At : https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-discount-pricing

 

Number of reagents are available in the market to carry out the platelet function tests. These reagents include collagen, thrombin, ADP, vasopressin, epinephrine and ristocetin. Collagen, ADP were used in routine platelet aggregation studies for the evaluation of qualitative platelet function disorders.

 

Market participants such as F. Hoffmann La-Roche Ltd., Drucker Diagnostics, Haemonetics Corporation, Sysmex Corporation, Siemens Healthineers, Chrono-log Corporation, Instrumentation Laboratory, Accriva Diagnostics, Matis Medical, Helena Laboratories Corporation, Sienco, Inc., Bio/Data Corporation, Tem Group, WerfenLife, S.A., Laboratory Corporation of America Holdings, Sentinel CH. S.p.A., and Aggredyne, Inc. are some of the key players operating in the concerned market.

 

Have Questions? Or make an Inquiry before buying this report Speak to Our Industry Expert:  https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/speak-to-analyst

 

Wednesday, 15 July 2020

Vaccine Adjuvants Market Share, Industry Size, Opportunities, Analysis and Forecast To 2027

The global Vaccine Adjuvants Market size is expected to reach USD 1,305.7 million by 2027 according to a new study by Polaris Market Research
Adjuvant is defined as a substance which in combination with vaccine invigorates antigen specific immune reactions to increase specificity and immunogenicity of marketed vaccines administered in any individual. Adjuvants augment the impact of a vaccine providing increased immunity towards any particular infectious disease. It triggers positive immune response by mimicking pathogen associated molecular pattern (PAMP), which include lipo-polysaccharide, liposomes, cell walls of bacteria, and endo-cytosed and un-methylated nucleic acids. Adjuvant imparts beneficial effects to vaccines in several ways such as increasing its potency to grasp the higher degree of immunogenicity, reducing the number of repeated vaccinations, antigen dose reduction, widening antibody responses of the individual, and inducing T-cell responses.


The global market is driven by the recent surge in infectious diseases, extensive research on vaccines, and funding from the government. European Union (EU) through EU programme Horizon 2020, has formed ENOVA, a network on vaccine adjuvants. This will bring both industry experts and stakeholders working in the areas of vaccine research and development and adjuvant research to reduce side effects and efficacy of new developing vaccines.

Market participants such as GlaxoSmithKline Plc, Novavax, Inc., Statens Serum Institut, Viscogel AB, VaxLiant LLC, Aphios Corporation, Moderna Inc., Sanofi Pasteur, Adjuvatis, Avanti Polar Lipids, Inc., MPV Technologies, CSL Limited, Vaxine Pty Ltd, SPI Pharma, CureVac AG, Sergeant Adjuvants, Agenus, Inc., OZ Biosciences, Adjuvants Unlimited Inc., and Adjuvants Euclid Canada Inc. are some of the key players operating in the concerned market.


 To speed up the process of nCOV vaccine development big players are collaborating with industry stakeholders. In February 2020, GSK and Coalition for Epidemic Preparedness Innovations (CEPI) collaborated to ease the out nCOV vaccine development with GSK’s vaccine adjuvant platform for other players in vaccine development. Similarly, in March 2020, iBio, a contract research organization (CRO) signed a definitive agreement with the Infectious Disease Research Institute (IDRI). The combination of iBio’s VLP antigen with the latter adjuvant expected to offer promising efficacy and safety characteristics.